2020
DOI: 10.1016/j.htct.2020.09.043
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles